TOOKAD soluble is indicated for adult patients with unilateral low risk localised prostate cancer and with a life expectancy ≥ 10 years and:- - Clinical stage up to T2a, - Gleason Score ≤ 6, based on high-resolution biopsy strategies, - PSA ≤ 10 ng/mL, - Up to 3 independent positive cores- mpMRI by 3T without endo-rectal coil showing normal MRI or unilateral tumor without evidence of capsular or seminal vesicle involvement or metastatic tumor to lymph nodes.TOOKAD is administered as part of focal Vascular-Targeted Photodynamic therapy (VTP).